Quintrio
Home

Stock overview

SOPHiA GENETICS SA Ordinary Shares

SOPH

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Last trade $7.31
Day change -$0.135 (-1.81%)
Day range $7.12 – $7.70
Volume 274,697
Market cap $637M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SOPH.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SOPH.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates

SOPHiA GENETICS reported a quarterly loss of $0.24 per share, missing consensus estimates of $0.13 loss by 84.62%, though revenues slightly exceeded expectations at $24.27 million. The stock has gained 52.3% year-to-date, significantly outperforming the S&P 500's 10.2% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market going forward.

GlobeNewswire Inc.

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

Benzinga

Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)

U.S. stock futures showed mixed performance on Wednesday with the Dow Jones declining while the S&P 500 and Nasdaq 100 advanced. Investors awaited the FOMC interest rate decision expected at 2:00 p.m. ET, with markets pricing a 99.6% likelihood of unchanged rates. Notable movers included La-Z-Boy surging 19.62% on strong earnings and a $300 million buyback, Amkor jumping 5.49% after signing a 10-year deal with TSMC, and SpaceX rising 3.22% following its Cursor AI acquisition.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.